Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGG492 in refractory partial seizures
NCT00887861Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in focal seizures comparing BGG492 with Placebo (2 arms). Primary endpoint: Efficacy of investigation drug versus Placebo in reducing the seizure rate at 7 days. Started Mar 2009; status: completed.
02
Drugs
selurampanel
03
Conditions
focal seizures
Beyond the preview
Go deeper on NCT00887861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887861.